Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$150
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Poniard Pharmaceuticals, Inc.Poniard Pharmaceuticals, Inc.0--515%-0.5

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$150.00
Enterprise Value$-343,850.00
Earnings per Share$-26.4
Beta-36.63
Outstanding Shares1,498,350

Return

Return on Equity-514.66%ROE
Return on Assets-207.37%
Return on Invested Capital-326.53%

Valuation & Multiples

P/E Ratio0P/E Ratio
PEG0PEG
Price to Sales-Price to Sales
Price to Book Ratio0.0Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.02
Enterprise Value to Net Income0
Total Debt to Enterprise-4.77
Debt to Equity0.53Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Poniard Pharmaceuticals, Inc.

7 employees
CEO: Robert F. Caspari

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types,...